Key messages

• Retrospective case series of 50 patients comparing treatment with erenumab and onabotulinum toxin A to onabotulinum toxin A alone in patients with chronic migraine
• The combination was significantly better in reducing the total number of monthly headaches and monthly migraine days than monotherapy with erenumab.
• The combination treatment was well tolerated without significant adverse events.